Lilly Completes Final Phase of Its Indianapolis Biotechnolo...(eers who modelmanufacturing processes to...)

Date:5/12/2008

eers who model manufacturing processes to eventually scale up commercial production of future Lilly biopharmaceuticals. The staff in K360 helps ensure a seamless transition from development to full-scale manufacturing - a notoriously complex process in biotechnology - giving Lilly speed to market and cost advantages over its biotech competitors.

The second phase, also opened in the fall of 2006, is a 10,000-square-foot research support facility (known as K361) that houses support staff members. In total, buildings K360 and K361 are home to nearly 300 scientists and support staff.

"This completed biotechnology complex gives us the ability to capitalize on the synergies of being colocated with our drug discovery in Indianapolis," said, Steven Paul, M.D., executive vice president of science and technology and president of Lilly Research Laboratories. "This is a state-of-the-art facility that allows us to move products through the pipeline with increased efficiencies, high quality and cost savings. This facility basically allows us to quadruple the throughput of our biotechnology pipeline."

"The company's investment in these facilities "gives Lilly a line of sight from discovery through development and into manufacturing, uniquely positioning us as a biopharmaceutical leader in the industry," said Bill Heath, Ph.D., vice-president of product research and development.

"Lilly is an incredible asset to our community," said Mayor Greg Ballard. "The company's decision to keep nearly 800 high-tech, high-paying jobs in Indianapolis is tremendous for our city and underscores the growing life sciences sector here in Indiana. As a Fortune 500 company, Lilly has played and will continue to play an important role in that sector's growth in Indianapolis."

Lilly has been a leader in biopharmaceuticals since 1922, when the company was the first to make and market insulin. Today Lilly is the fifth largest biotechnology company in the world as measured
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Lilly CEO Urges Policy Prescriptions to Help Ensure Public and Private Biotech Investments Generate Dividends and U.S. Job Growth
2. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
3. Lilly Reports Solid First-Quarter Results
4. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
5. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
6. Lilly Announces Termination of AIR Insulin Program
7. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
8. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
9. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
10. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
11. Lilly Declares Fourth-Quarter Dividend